IO Biotech Plans Cylembio Filing Despite ‘Narrowly Missed’ Phase III Endpoint

 
• By Mandy Jackson
  
IO Biotech sees its Phase III data as meaningful for melanoma patients (Shutterstock)

More from Clinical Trials

More from R&D